Market Trends of Global Cell Signaling Industry
This section covers the major market trends shaping the Cell Signaling Market according to our research experts:
The AKT Signaling Pathway Segment is Expected to Register Good Growth Over the Forecast Period
The AKT signaling pathway, also known as the survival pathway, is responsible for the increased proliferation, loss of apoptosis signaling, and cell growth. The AKT signaling pathway is the most commonly dysregulated pathway in the most prevalent forms of cancer. A number of drugs have been designed based on the rationale that inhibition of AKT pathway, could help in achieving therapeutic results. A number of drugs based on AKT signaling are currently in various stages of clinical trials.
In the treatment of advanced-stage COVID-19 patients, AKT is found as a potential therapeutic target. Its inhibition will potentially suppress the cytokine storm, fibroproliferation, pathological inflammation, and platelet activation associated with COVID-19. It also promotes resolution and prevents scarring in injured lungs. As per the study published "AKT a viable option to treat advanced-stage COVID-19 patients" in 2020, pharmacological inhibition of AKT has also been reported to inhibit angiotensin-converting enzyme 2 (ACE2) expression, a receptor for the virus entry into the lung cells, and targeting AKT for COVID-19 looks like a viable option.
Over the forecast period, this market is expected to grow, as commercial diagnostic tests are expected to emerge based on down-regulation of the AKT pathway.
North America is Expected to Dominate the Market Over the Forecast Period
North America holds a significant share of the cell signaling market and is expected to show a similar trend over the forecast period, without significant fluctuations. The cell signaling market is expected to witness numerous growth opportunities during the pandemic, with cell signaling pathways being utilized as experimental virology platforms to study the immune responses and infectivity of SARS-CoV-2. Most of the major players have been involved in R&D activities regarding cell signaling pathways. The mortality in most COVID-19 patients is due to the presence of a cytokine storm, which is induced by the virus. The excessive production of these proinflammatory cytokines leads to acute respiratory distress syndrome aggravation and widespread tissue damage, which results in multi-organ failure and death. Thus, targeting cell signaling pathways such as cytokines during the management of COVID-19 may lead to the reduction of the mortality rate and improved outcomes. This is likely to have a positive impact on the market studied.
In the United States, for the fiscal year 2021, USD 575 million was granted by the federal government for the National Cancer Institute (NCI) budget for breast cancer research, USD 225 million for colorectal cancer research, and USD 250 million for leukemia. Additionally, the estimates available on the National Institute of Health Portal for stem cell-based research indicate a cumulative funding budget of more than USD 3 billion for research in various fields of stem cell applications. The need for cell signaling in cancer research plays a vital role in the progressive growth of the cell signaling market in the United States. The growing funding in cancer research and stem cell research are directly causing an increase in cell signaling research, particularly in the United States. The increasing trend of increment in research funding is expected to lead to the growth of the market studied in the United States.
